Literature DB >> 29975155

Mesenchymal chondrosarcoma of the orbit: imaging features of CT and MRI.

Mitsuteru Tsuchiya1, Takayuki Masui1, Yoshiro Otsuki2, Harumi Sakahara3.   

Abstract

OBJECTIVE: : Mesenchymal chondrosarcoma (MCS) of the orbit is a rare and aggressive form of chondrosarcoma. The purpose of this study was to retrospectively identify the imaging features of mesenchymal chondrosarcoma of the orbit.
METHODS: : This study included five patients with histologically confirmed MCS of the orbit who had undergone either CT, MRI, or both. Images were evaluated for the following: location, size, margin, CT density and presence or absence of calcification and/or ossification, MRI findings including dynamic contrast-enhancement and time-intensity curves.
RESULTS: : CT was performed in four of the five patients, and all four (100%) demonstrated calcification and ossification of the mass. MRI was performed in all five patients. In two patients (40%), the mass demonstrated areas of hyperintensity on T1 weighted images.
CONCLUSION: : The presence of a well-defined, orbital mass with calcification and ossification on CT and, marked heterogenous enhancement and a rapid-washout pattern on dynamic MRI indicate a high probability of MCS of the orbit. In addition, MCS of the orbit can demonstrate areas of hyperintensity on T1 weighted images, representing bone marrow fat tissue of ossification. ADVANCES IN KNOWLEDGE:: MCS of the orbit is a highly malignant tumor, and early diagnosis by imaging is important. Radiologists should be aware of the imaging features of MCS of the orbit.

Entities:  

Mesh:

Year:  2018        PMID: 29975155      PMCID: PMC6350477          DOI: 10.1259/bjr.20170579

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  1 in total

1.  Multimodal therapy in the management of primary orbital mesenchymal chondrosarcoma.

Authors:  Yun Zhao; Jing-Wen Hui; Sha-Sha Yu; Jin-Yong Lin; Hong Zhao
Journal:  Int J Ophthalmol       Date:  2022-02-18       Impact factor: 1.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.